As of September 30, 2024, the Company had cash, cash equivalents and marketable securities totaling $203.7 million, which provides projected cash runway into 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics initiated with an Outperform at Oppenheimer
- Larimar Therapeutics initiated with an Outperform at Wedbush
- Wedbush bullish on Larimar Therapeutics, initiates with an Outperform
- Larimar Therapeutics initiated with a Buy at H.C. Wainwright
- Larimar Therapeutics initiated with a Buy at JonesResearch